表紙
市場調査レポート

虚血症 :パイプライン分析

Ischemia - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229757
出版日 ページ情報 英文 223 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
虚血症 :パイプライン分析 Ischemia - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 223 Pages
概要

心筋に送られる血流と酸素が不足することを虚血症といいます。症候は、胸の左側の痛み(狭心症)、首あるいは顎の痛み、肩や腕の痛み、冷や汗、息切れ、悪心や吐き気などです。心筋虚血症は、冠動脈疾患(アテローム性動脈硬化症)や凝血、冠動脈攣縮、重篤な疾患などによって引き起こされる可能性があります。心筋虚血症を発症するリスクを高める素因に喫煙、糖尿病、高血圧症、高濃度の血中コレステロール値およびトリグリセリド値、運動不足、肥満、家族の病歴などがあります。

当レポートでは、虚血症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

虚血症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Alize Pharma SAS
  • Amarantus Bioscience Holdings, Inc.
  • AnGes MG, Inc.
  • Apceth GmbH & Co. KG
  • Athersys, Inc.
  • Baxter International Inc.
  • Cellmid Limited
  • CoDa Therapeutics, Inc.
  • DNAVEC Corporation
  • GlaxoSmithKline plc
  • Hemostemix Ltd
  • Human Stem Cells Institute
  • IntelliCell BioSciences Inc.
  • Juventas Therapeutics, Inc.
  • Kasiak Research Pvt. Ltd.
  • Lixte Biotechnology Holdings, Inc.
  • Mast Therapeutics, Inc.
  • Miltenyi Biotec GmbH
  • Mirrx Therapeutics A/S
  • Multi Gene Vascular Systems Ltd
  • NeoStem, Inc.
  • Nuo Therapeutics, Inc.
  • Nyken BV
  • Opsona Therapeutics Ltd.
  • Pathfinder Cell Therapy, Inc.
  • PharmaIN Corporation
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • Regado Biosciences, Inc.
  • ReNeuron Group plc
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Stempeutics Research Private Limited
  • Taxus Cardium Pharmaceuticals Group Inc.
  • TikoMed AB
  • Vericel Corporation
  • ViroMed Co., Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AB-002
  • ACP-01
  • ALD-301
  • Alecmestencel-T
  • alferminogene tadenovec
  • AMR-001
  • AMRS-001
  • AntimiR-199a
  • Aptamers for Cardiovascular Deseases
  • ASCT-01
  • Autologous Vascular Cells Therapy
  • AZP-531
  • beperminogene perplasmid
  • bucillamine
  • CD5-2
  • Cell Therapy for Critical Limb Ischemia
  • Cell Therapy for Ischemia
  • Cellgram for Severe Lower Limb Ischemia
  • Cinepazide Mesylate
  • CMK-103
  • DVC1-0101
  • EP-80317
  • Gene Therapy for Ischemic Heart Failure
  • Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Deseases
  • GSK-1278863
  • ixmyelocel-T
  • JVS-100
  • JVS-200
  • LB-100
  • LB-102
  • MicroRNA for Ischemia
  • MultiGeneAngio
  • MultiStem
  • NRP-2945
  • NYK-1112
  • Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Desease
  • Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders
  • OPN-305
  • Pathfinder Cells
  • Peptagon
  • PGC Based hbEGF
  • PMC-6
  • Protein for Myocardial Infarction and Critical Limb Ischemia
  • PT-00114
  • Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia
  • Recombinant Protein for Critical Limb Ischemia
  • Recombinant Protein for Ischemia
  • Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology
  • Refacell-CLI
  • ReN-009
  • Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury
  • Small Molecules for Ischemia and Reperfusion Injury
  • Small Molecules for Renal Failure and Renal Ischemia
  • Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia
  • Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma
  • Small Molecules to Inhibit Mst1 for Myocardial Ischemia
  • Stem Cell Therapy for Cardiovascular Desease
  • Stem Cell Therapy for Cardiovascular Deseases
  • Stem Cell Therapy for Cardiovascular Deseases
  • Stem Cell Therapy for Critical Limb Ischemia
  • Stem Cell Therapy for Critical Limb Ischemia
  • Stem Cell Therapy for Critical Limb Ischemia
  • Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia
  • Stempeucel
  • Stromal Cell Therapy for Critical Limb Ischemia
  • TM-700
  • vepoloxamer
  • VM-202

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7314IDB

Summary

Global Markets Direct's, 'Ischemia - Pipeline Review, H2 2015', provides an overview of the Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ischemia Overview
  • Therapeutics Development
    • Pipeline Products for Ischemia - Overview
    • Pipeline Products for Ischemia - Comparative Analysis
  • Ischemia - Therapeutics under Development by Companies
  • Ischemia - Therapeutics under Investigation by Universities/Institutes
  • Ischemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ischemia - Products under Development by Companies
  • Ischemia - Products under Investigation by Universities/Institutes
  • Ischemia - Companies Involved in Therapeutics Development
    • Alize Pharma SAS
    • Amyndas Pharmaceuticals LLC
    • AnGes MG, Inc.
    • Apceth GmbH & Co. KG
    • Athersys, Inc.
    • Baxalta Incorporated
    • Caladrius Biosciences, Inc.
    • Cellmid Limited
    • CoDa Therapeutics, Inc.
    • CohBar, Inc.
    • Cynata Therapeutics Limited
    • DNAVEC Corporation
    • GlaxoSmithKline Plc
    • Hemostemix Ltd
    • IntelliCell BioSciences Inc.
    • Juventas Therapeutics, Inc.
    • Kasiak Research Private Limited
    • Lixte Biotechnology Holdings, Inc.
    • Mesoblast Limited
    • Miltenyi Biotec GmbH
    • Mirrx Therapeutics A/S
    • Multi Gene Vascular Systems Ltd
    • NoNO, Inc.
    • Nyken BV
    • Pathfinder Cell Therapy, Inc.
    • Pharmicell Co., Ltd.
    • Pluristem Therapeutics Inc.
    • Protagenic Therapeutics Inc.
    • ReNeuron Group Plc
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Stempeutics Research Private Limited
    • Targazyme, Inc.
    • Taxus Cardium Pharmaceuticals Group Inc.
    • TikoMed AB
    • U.S. Stem Cell, Inc.
    • Vericel Corporation
    • ViroMed Co., Ltd.
  • Ischemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-002 - Drug Profile
    • ACP-01 - Drug Profile
    • AdipoCell - Drug Profile
    • Alda-1 - Drug Profile
    • Alecmestencel-T - Drug Profile
    • alferminogene tadenovec - Drug Profile
    • AntimiR-199a - Drug Profile
    • ASCT-01 - Drug Profile
    • Autologous Vascular Cells Therapy - Drug Profile
    • AZP-531 - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • bucillamine - Drug Profile
    • CD-52 - Drug Profile
    • Cell Therapy for Critical Limb Ischemia - Drug Profile
    • Cell Therapy for Ischemia - Drug Profile
    • Cell Therapy for Ischemia - Drug Profile
    • Cellgram for Severe Lower Limb Ischemia - Drug Profile
    • Cinepazide Mesylate - Drug Profile
    • CLBS-12 - Drug Profile
    • CMK-103 - Drug Profile
    • daprodustat - Drug Profile
    • DVC1-0101 - Drug Profile
    • EP-80317 - Drug Profile
    • Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
    • Humanin - Drug Profile
    • ixmyelocel-T - Drug Profile
    • JVS-100 - Drug Profile
    • JVS-200 - Drug Profile
    • LB-100 - Drug Profile
    • LB-102 - Drug Profile
    • MicroRNA for Ischemia - Drug Profile
    • MPC-25IC - Drug Profile
    • MultiGeneAngio - Drug Profile
    • MultiStem - Drug Profile
    • NYK-1112 - Drug Profile
    • Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile
    • Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile
    • Pathfinder Cells - Drug Profile
    • Peptagon - Drug Profile
    • PLX-PAD - Drug Profile
    • PMC-6 - Drug Profile
    • Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile
    • PT-00114 - Drug Profile
    • Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile
    • Recombinant Protein for Critical Limb Ischemia - Drug Profile
    • Recombinant Protein for Ischemia - Drug Profile
    • Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
    • Refacell-CLI - Drug Profile
    • Rejuveinix - Drug Profile
    • ReN-009 - Drug Profile
    • Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
    • Small Molecules for Ischemia and Reperfusion Injury - Drug Profile
    • Small Molecules for Renal Failure and Renal Ischemia - Drug Profile
    • Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile
    • Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile
    • Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
    • Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
    • Stem Cell Therapy for Cardiovascular Disease - Drug Profile
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
    • Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile
    • Stempeucel - Drug Profile
    • Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile
    • TM-700 - Drug Profile
    • TZ-101 - Drug Profile
    • VM-202 - Drug Profile
  • Ischemia - Recent Pipeline Updates
  • Ischemia - Dormant Projects
  • Ischemia - Discontinued Products
  • Ischemia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ischemia, H2 2015
  • Number of Products under Development for Ischemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Ischemia - Pipeline by Alize Pharma SAS, H2 2015
  • Ischemia - Pipeline by Amyndas Pharmaceuticals LLC, H2 2015
  • Ischemia - Pipeline by AnGes MG, Inc., H2 2015
  • Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2015
  • Ischemia - Pipeline by Athersys, Inc., H2 2015
  • Ischemia - Pipeline by Baxalta Incorporated, H2 2015
  • Ischemia - Pipeline by Caladrius Biosciences, Inc. , H2 2015
  • Ischemia - Pipeline by Cellmid Limited, H2 2015
  • Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2015
  • Ischemia - Pipeline by CohBar, Inc., H2 2015
  • Ischemia - Pipeline by Cynata Therapeutics Limited, H2 2015
  • Ischemia - Pipeline by DNAVEC Corporation, H2 2015
  • Ischemia - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Ischemia - Pipeline by Hemostemix Ltd, H2 2015
  • Ischemia - Pipeline by IntelliCell BioSciences Inc., H2 2015
  • Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2015
  • Ischemia - Pipeline by Kasiak Research Private Limited, H2 2015
  • Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
  • Ischemia - Pipeline by Mesoblast Limited, H2 2015
  • Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2015
  • Ischemia - Pipeline by Mirrx Therapeutics A/S, H2 2015
  • Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015
  • Ischemia - Pipeline by NoNO, Inc., H2 2015
  • Ischemia - Pipeline by Nyken BV, H2 2015
  • Ischemia - Pipeline by Pathfinder Cell Therapy, Inc., H2 2015
  • Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2015
  • Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2015
  • Ischemia - Pipeline by Protagenic Therapeutics Inc., H2 2015
  • Ischemia - Pipeline by ReNeuron Group Plc, H2 2015
  • Ischemia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015
  • Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2015
  • Ischemia - Pipeline by Targazyme, Inc., H2 2015
  • Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2015
  • Ischemia - Pipeline by TikoMed AB, H2 2015
  • Ischemia - Pipeline by U.S. Stem Cell, Inc., H2 2015
  • Ischemia - Pipeline by Vericel Corporation, H2 2015
  • Ischemia - Pipeline by ViroMed Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Ischemia Therapeutics - Recent Pipeline Updates, H2 2015
  • Ischemia - Dormant Projects, H2 2015
  • Ischemia - Dormant Projects (Contd..1), H2 2015
  • Ischemia - Dormant Projects (Contd..2), H2 2015
  • Ischemia - Dormant Projects (Contd..3), H2 2015
  • Ischemia - Dormant Projects (Contd..4), H2 2015
  • Ischemia - Dormant Projects (Contd..5), H2 2015
  • Ischemia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Ischemia, H2 2015
  • Number of Products under Development for Ischemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top